RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer

    loading  Checking for direct PDF access through Ovid



Aberrations in mediators of Ras signaling may increase the risk of developing recurrent endometrial carcinoma.

Patients and methods

Primary tumors of patients with (n=44) and without (n=44) recurrent stage I endometrioid endometrial carcinoma were compared regarding the presence of K-ras mutations (codons 12 and 13), B-raf mutations (V599), and RASSF1A gene promoter methylation.


K-ras mutations were present in 18% of the patients independent of recurrent disease. No B-raf mutations were found. RASSF1A methylation was demonstrated in 85% of endometrial carcinomas, independent of recurrence. The presence of K-ras mutations and RASSF1A promoter methylation were not related, either directly or inversely. Analysis in premenopausal endometrial carcinomas demonstrated K-ras mutations in 40%, no B-raf mutations, and RASSF1A promoter methylation in 70% of the cases. RASSF1A methylation was also observed in samples of cyclic (n=14), hyperplastic (n=8), and atrophic (n=13) endometrial tissues in 21%, 50% and 38%, respectively.


RASSF1A methylation was observed in a high frequency in endometrioid endometrial carcinoma whereas K-ras and B-raf mutations were observed in a low frequency. No association was observed with the development of recurrent disease. High-frequency RASSF1A methylation in premenopausal carcinomas and an increased frequency in endometrial hyperplasia indicate that this may be an early event in endometrial carcinogenesis.

Related Topics

    loading  Loading Related Articles